Travere Therapeutics

TVTX

Market cap $2.05B

Overview Fund Activity

23.01 USD

-0.46

1.96%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

23.01

0.00

0%

1 day

-1.96%

5 days

8.28%

1 month

22.26%

3 months

56.74%

6 months

10.25%

Year to date

21.3%

1 year

61.25%

5 years

17.88%

10 years

-19.46%

About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Employees: 385

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

337% more call options, than puts

Call options by funds: $32.5M | Put options by funds: $7.43M

10% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 69

2.76% more ownership

Funds ownership: 110.44% [Q1] → 113.21% (+2.76%) [Q2]

4% less funds holding

Funds holding: 217 [Q1] → 209 (-8) [Q2]

15% less first-time investments, than exits

New positions opened: 40 | Existing positions closed: 47

16% less capital invested

Capital invested by funds: $1.77B [Q1] → $1.49B (-$284M) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

9% upside

Avg. target

$34

48% upside

High target

$47

104% upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Stifel Alex Thompson	$25	Hold Maintained	12 Sep 2025
Wells Fargo Mohit Bansal	$35	Overweight Maintained	11 Sep 2025
HC Wainwright & Co. Joseph Pantginis	$47	Buy Reiterated	10 Sep 2025
Scotiabank Greg Harrison	$31	Sector Outperform Maintained	7 Aug 2025
Wedbush Laura Chico	$32	Outperform Maintained	7 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 14 articles about TVTX published over the past 30 days

Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS

Initiating coverage on Travere Therapeutics with a "Buy: rating, citing strong growth potential for its kidney drug Filspari (sparsentan). Company's Filspari is FDA-approved for IgAN, with Q2 2025 U.S. net product revenues growing by 165% year-over-year to $71.9 million. A key catalyst is the January 13, 2026 PDUFA date for Filspari's sNDA in FSGS, potentially making it the first approved treatment for this rare kidney disorder.

Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 69,300 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Zacks Investment Research

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval

I am upgrading Travere Therapeutics, Inc. to a Buy, as the FDA's decision not to hold an AdCom suggests a favorable path for Filspari in FSGS. Filspari's strong sales growth, improved financials, and recent REMS label relaxation demonstrate real-world success and de-risk the investment case. While competition in IgAN is intensifying, a win in FSGS could make Filspari a blockbuster, driving significant upside for Travere's valuation.

Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval

Investors Business Daily

Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High

Shares of Travere Therapeutics shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug, Filspari.

Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

SAN DIEGO--(BUSINESS WIRE)---- $TVTX #FSGS--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee is no longer needed. The sNDA remains under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026. “FSGS is a leadin.

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Eric Dube - President, CEO & Director Peter Heerma - Chief Commercial Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Sadia Rahman - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Great. Thank you very much for joining us today.

Travere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:45 PM EDT Company Participants Eric Dube - President, CEO & Director Peter Heerma - Chief Commercial Officer Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Hello, everyone.

Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

SAN DIEGO--(BUSINESS WIRE)---- $TVTX #ICIEM2025--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company shared two oral presentations in classical homocystinuria (HCU) at the International Congress of Inborn Errors of Metabolism, taking place September 2-6 in Kyoto, Japan. New long-term data from Cohort 6 of the Phase 1/2 COMPOSE open-label extension (OLE) Study demonstrated that at the target dose of 2.5 mg/kg twice weekly, participants treated with pegtibatinase in the OLE maintained signific.

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

See News Rankings

Charts implemented using Lightweight Charts™